Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | January 18, 2022 |
| Target | Daiichi Sankyo - Eight Branded Products |
| Sector | Life Science |
| Buyer(s) | Cosette Pharmaceuticals |
| Sellers(s) | Daiichi Sankyo |
| Deal Type | Divestiture |
FILTER BY
Cosette Pharmaceuticals is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. The current products focus on complex dosage forms including topical creams, ointments, oral liquids/solutions, suppositories, and injectables. Cosette Pharmaceuticals is based in Bridgewater, New Jersey.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science | 1 of 2 |
| Type: Divestiture | 1 of 2 |
| Country: Japan | 1 of 1 |
| Year: 2022 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-12-20 |
Vyleesi
United States Vyleesi is a treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). |
Buy | $171M |
| Category | Company |
|---|---|
| Founded | 1899 |
| Sector | Life Science |
| Employees | 19,765 |
| Revenue | 1.89T JPY (2025) |
Daiichi Sankyo manufactures pharmaceuticals for human/veterinary use and medical tools and equipment. It also researches and promotes products through related companies throughout the world. The Group also produces food, food additives, livestock feeds, and agrochemicals. Daiichi Sankyo was founded in 1899 and is based in Tokyo, Japan.
| Deal Context for Seller | # |
|---|---|
| Overall | 4 of 4 |
| Sector: Life Science | 3 of 3 |
| Type: Divestiture | 4 of 4 |
| Country: Japan | 1 of 1 |
| Year: 2022 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-04-01 |
Daiichi Sankyo Altkirch Sarl
Altkirch, France Daiichi Sankyo Altkirch Sarl is focused on the manufacturing of raw materials for pharmaceuticals based in Altkirch, France. |
Sell | - |
